James Lewis

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, James Lewis sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).

5 total trials 1 currently recruiting 4 completed later-stage tilt upper quartile by trial count

James Lewis: 5 sponsored US clinical trials, 1 recruiting.

James Lewis sponsors 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. 2 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Inflammatory Bowel Disease, with 1 trials.

Upper-quartile sponsor footprint

James Lewis sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Where James Lewis enrollment is open (later-stage tilt)

1 recruiting of 5 indexed (20% open); 4 completed (80%).

Phase mix: 2 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Inflammatory Bowel Disease (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

James Lewis: open-pipeline peers nationwide

Peers matched on 5 registered trials and 20% open enrollment, not the therapeutic-area sidebar.

James Lewis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 4.95.05.055.05.05.1 0%5%10%15%20%25% Total trials Recruiting share James Lewis4YouandMeAbbott Rapid DxAccess Business GroupAcera SurgicalAlign TechnologyAltruBioAlvernia UniversityAmazentis
James Lewis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

James Lewis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 5 trials (± recruiting share)

Sponsors near 20% open enrollment (± trial volume)

What to do with this James Lewis page

5 registered trials is a research-attention snapshot, not an endorsement of James Lewis or any single study.

  • 1 of James Lewis's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Inflammatory Bowel Disease is the condition James Lewis studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Inflammatory Bowel Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

James Lewis pipeline card: 5 registered trials from official public datasets.Report a data error.